Phio Pharmaceuticals Corp expected to post a loss of $1.23 a share - Earnings Preview
28/03/2025 20:58
Phio Pharmaceuticals Corp PHIO.OQ PHIO.O is expected to report resultson March 31 (estimated) for the period ending December 31 2024 LSEG's mean analyst estimate for Phio Pharmaceuticals Corp is for a loss of $1.23 per share. The one available analyst rating on the shares is "buy". The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Phio Pharmaceuticals Corp is $4.00, above its last closing price of $1.31. This summary was machine generated March 28 at 20:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing